Kazia Therapeutics (KZIA) Short term Debt (2018 - 2025)

Kazia Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $9.3 million for Q4 2025.

• Quarterly Short term Debt rose 605.56% year-over-year to $9.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (up 605.56% YoY) and the FY2025 annual result came in at $2.0 million, up 382.88% from the prior year.
• Short term Debt was $9.3 million for Q4 2025 at Kazia Therapeutics, up from $2.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $9.3 million in Q4 2025 and bottomed at -$1.3 million in Q2 2022.
• A 4-year average of $2.6 million and a median of $1.3 million in 2024 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt sank 76.43% — and 2025, when it surged 605.56%.
• Kazia Therapeutics' Short term Debt stood at -$1.3 million in 2022, then surged by 524.56% to $5.6 million in 2023, then plunged by 76.43% to $1.3 million in 2024, then jumped by 605.56% to $9.3 million in 2025.
• Business Quant data shows KZIA's Short term Debt at $9.3 million in Q4 2025, $2.0 million in Q2 2025, and $1.3 million in Q4 2024.